• In May 2026, Charles River Laboratories reported first-quarter revenue of US$995.83 million with a net loss of US$14.84 million, raised full-year GAAP EPS guidance to US$5.35–US$5.85, completed a US$200 million buyback, and detailed higher long-lived asset impairments alongside continued investment in AI-enabled digital pathology and cell therapy testing collaborations.
• These updates highlight Charles River’s effort to reshape its business mix and efficiency profile, using automation, advanced biologics capabilities, and capital deployment to support margin improvement while its operations undergo transition.
• Next, we’ll examine how the upgraded earnings guidance and expansion in digital pathology and cell therapy testing affect Charles River’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 44 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Charles River Laboratories International Investment Narrative Recap

To own Charles River Laboratories, you need to believe its shift toward higher value services like AI-enabled digital pathology and cell and gene therapy testing can offset pressure on its traditional animal-based research. Right now, the key near term catalyst is evidence that demand stabilizes and margins recover, while the biggest risk is that cancellations and weaker bookings persist. The latest quarter, with modest revenue growth but a net loss and higher impairments, does not fundamentally change those stakes.

The most relevant update here is Charles River’s push into AI-powered digital pathology, which aims to cut pathology timelines by at least a week and improve pathologist efficiency by around 20% today, with more benefits targeted as new QC tools are rolled out. Combined with fresh collaborations in cell therapy testing, this reinforces the idea that any improvement in earnings quality will likely come from productivity gains and complex biologics work, rather than simple volume growth.

Yet investors should also weigh how rising cancellations and a book to bill ratio below 1x could limit the benefits of these initiatives...

Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028. This requires 2.8% yearly revenue growth and a $552.4 million earnings increase from -$69.2 million today.

Uncover how Charles River Laboratories International's forecasts yield a $215.73 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts expect revenues near US$4.4 billion and earnings around US$583 million by 2029, arguing that faster NAMs adoption and deeper digitalization could radically lift margins, which is a much more upbeat view than consensus and could be reshaped again by Charles River’s new AI pathology and cell therapy moves.

Explore 4 other fair value estimates on Charles River Laboratories International - why the stock might be worth 50% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.